Journal
ADVANCES IN THERAPY
Volume 30, Issue 8, Pages 713-726Publisher
SPRINGER
DOI: 10.1007/s12325-013-0047-y
Keywords
Disease modifying anti-rheumatic drugs; Janus kinases; Janus kinase inhibitors; Rheumatology; Rheumatoid arthritis; Small molecules; Tofacitinib
Ask authors/readers for more resources
The management of rheumatoid arthritis has seen a dramatic improvement with the introduction of a range of biological disease modifying anti-rheumatic drugs (DMARDs) in recent years. Nonetheless, a proportion of patients remain resistant or intolerant to multiple conventional and biological DMARDs, so innovative strategies are needed to offer patients new therapeutic options. Tofacitinib is the first of a new class of orally active DMARDs, with immunomodulating effects through inhibition of intracellular Janus kinase (JAK) pathways. It has been recently licensed for treatment of adults with moderate to severe RA in the US, Japan, and Russia. In this review the authors evaluate the efficacy and safety of tofacitinib in RA, focusing predominantly on the phase 3 study data.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available